Summary & Overview
HCPCS C9497: Loxapine Inhalation Powder, 10 mg
HCPCS Level II code C9497 identifies loxapine inhalation powder, 10 mg, an acute-delivery inhaled antipsychotic formulation used for rapid management of agitation in psychiatric settings. Nationally, this code matters because it captures a distinct route and formulation of a psychotropic medication that can affect site-of-service utilization, billing workflows, and payer coverage policies for emergency and inpatient behavioral health care. Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise reference to what the code represents, typical sites of service, and the clinical context for use. The publication outlines payer coverage scope and common billing considerations, summarizes available benchmarks where present, and highlights policy and coding clarifications that influence claim adjudication for inhaled loxapine. The material is intended to inform billing staff, revenue cycle leaders, and policy analysts about the code’s clinical role and billing implications at a national level. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9497 represents Loxapine, inhalation powder, 10 mg. This billing code denotes the drug formulation delivered as an inhaled powder for acute treatment of agitation associated with certain psychiatric conditions.
-
Service type: Inhalation medication administration
-
Typical site of service: Emergency department, psychiatric emergency settings, inpatient psychiatric units, or other acute care settings where inhaled medication is administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with acute agitation related to a psychotic disorder presents to an emergency department or behavioral health urgent care. The clinician evaluates airway, breathing, and circulation, performs a focused psychiatric and medical assessment, and determines that rapid control of agitation is needed and that inhaled loxapine is appropriate. A respiratory assessment is documented and pulmonary contraindications (such as active bronchospasm) are ruled out. The medication C9497 (loxapine, inhalation powder, 10 mg) is administered via the proprietary inhaler in a monitored setting with pulse oximetry and trained staff available to manage potential respiratory events. Post-administration observation includes monitoring for sedation, oversedation, extrapyramidal symptoms, and respiratory adverse effects. Disposition options include discharge with outpatient follow-up for stable patients or inpatient psychiatric admission if ongoing risk is identified.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
51 | Multiple procedures | Use when multiple distinct procedures or services are billed on the same date and payer requires the modifier to indicate multiple procedures; apply per payer guidance when applicable. |